

CELLTECH GROUP PLC
Form 6-K
March 29, 2004

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a - 16 or 15d - 16 of

the Securities Exchange Act of 1934

For the month of **March, 2004**

Commission File Number: **1-10817**

CELLTECH GROUP PLC

(Translation of registrant's name into English)

208 Bath Road, Slough, Berkshire SL1 3WE ENGLAND

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

(If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____).

Enclosure 1: Holding(s) in Company announcement dated 16 March 2004

Enclosure 2: Holding(s) in Company announcement dated 22 March 2004

SCHEDULE 10

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Name of company

Celltech Group plc

2. Name of shareholder having a major interest

AMVESCAP PLC as agent for the ICVC named below.

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18

INVESCO Perpetual UK Investment Series

4. Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them

Unknown

5. Number of shares / amount of stock acquired

250,000

6. Percentage of issued class

0.09%

7. Number of shares / amount of stock disposed

N/a

8. Percentage of issued class

N/a

9. Class of security

Ordinary 50p shares

10. Date of transaction

12 March 2004

11. Date company informed

16 March 2004

12. Total holding following this notification

28,005,327

13. Total percentage holding of issued class following this notification

10.08%

14. Any additional information

This holding is included in the overall holding of 15.15% disclosed by AMVESCAP on 23 February 2004.

15. Name of contact and telephone number for queries

Anita Dowling Tel. 01753 777106

16. Name and signature of authorised company official responsible for making this notification

J A D Slater

Date of notification

16 March 2004

The FSA does not give any express or implied warranty as to the accuracy of this document or material and does not accept any liability for error or omission. The FSA is not liable for any damages (including, without limitation, damages for loss of business or loss of profits) arising in contract, tort or otherwise from the use of or inability to use this document, or any material contained in it, or from any action or decision taken as a result of using this document or any such material.

SCHEDULE 10

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Name of company

Celltech Group plc

2. Name of shareholder having a major interest FMR Corp and its direct and indirect subsidiaries and

Fidelity International Limited (FIL) and its direct and indirect subsidiaries

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18

Non-beneficial holder

4. Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them

| | |
|---|------------|
| State Street Nominees Limited | 527,612 |
| Chase Nominees Limited | 2,800,978 |
| State Street Bank & Trust Company | 437,100 |
| HSBC | 258,300 |
| Bank of New York | 2,500 |
| Chase Nominees Ltd | 23,600 |
| State Street Bank & Trust | 215,822 |
| State Street Nominees Ltd | 56,810 |
| Lloyds Bank Nominees Limited | 346,800 |
| Brown Brothers Harriman | 12,900 |
| JP Morgan Chase | 105,000 |
| Northern Trust | 61,700 |
| Morgan Stanley & Co | 44,400 |
| Chase Nominees | 14,507,583 |
| Chase Manhattan Bank London | 1,678,990 |
| HSBC Client Holdings Nominee (UK) Limited | 196,500 |
| Deutsche Bank | 15,000 |
| Citibank | 277,300 |
| HSBC | 125,814 |
| Bank of New York London | 259,100 |
| Chase Nominees Ltd | 144,300 |
| Northern Trust | 71,700 |
| Chase Nominees | 1,230,080 |
| Nortrust Nominees Ltd | 826,926 |
| HSBC Client Holdings Nominee (UK) Limited | 2,578,974 |
| Chase Manhattan Bank London | 752,648 |
| Northern Trust | 1,176,300 |
| JP Morgan | 739,311 |
| Bank of New York London | 1,280,600 |
| Morgan Stanley | 398,600 |
| Deutsche Bank | 337,735 |
| Mellon Nominees Ltd | 33,700 |
| State Street Nominees Ltd | 337,300 |
| Bank of New York Brussels | 534,041 |
| State Street Bank & Trust | 429,879 |
| National Australia Bank | 8,600 |
| PICG | 4,400 |
| Chase Manhattan Bank AG Frankfurt | 81,655 |
| Citibank | 146,300 |
| J P Morgan | 23,700 |

Edgar Filing: CELLTECH GROUP PLC - Form 6-K

| | |
|--|---------|
| State Street Hong Kong | 10,600 |
| Bankers Trust | 58,900 |
| Clydesdale Bank (Head Office) Nominees Limited | 205,300 |
| HSBC Client Holdings Nominee (UK) Limited | 200 |

5. Number of shares / amount of stock acquired

2,447,721 (since last notification)

6. Percentage of issued class

0.88%

7. Number of shares / amount of stock disposed

N/A

8. Percentage of issued class

N/A

9. Class of security

50p Ordinary Shares

10. Date of transaction

22 March 2004

11. Date company informed

22 March 2004

12. Total holding following this notification

33,365,558

13. Total percentage holding of issued class following this notification

12.01%

14. Any additional information

15. Name of contact and telephone number for queries

Cheryl Cramer Tel: 01753 447933

16. Name and signature of authorised company official responsible for making this notification

J A D Slater

Date of notification

22 March 2004

The FSA does not give any express or implied warranty as to the accuracy of this document or material and does not accept any liability for error or omission. The FSA is not liable for any damages (including, without limitation, damages for loss of business or loss of profits) arising in contract, tort or otherwise from the use of or inability to use this document, or any material contained in it, or from any action or decision taken as a result of using this document or any such material.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PLC

CELLTECH GROUP

(Registrant)

ALLEN

By: /s/ PETER

Officer

Peter Allen
Chief Financial

Dated: 29 March, 2004